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Malignant germ cell tumors (GCT) are the most common malignant tumors in young men between 18 and 40 years. The correct
identiﬁcation of histological subtypes, in diﬃcult cases supported by immunohistochemistry, is essential for therapeutic
management. Furthermore, biomarkers may help to understand pathophysiological processes in these tumor types. Two GCT
cell lines, TCam-2 with seminoma-like characteristics, and NTERA-2, an embryonal carcinoma-like cell line, were compared by
a quantitative proteomic approach using high-resolution mass spectrometry (MS) in combination with stable isotope labelling
by amino acid in cell culture (SILAC). We were able to identify 4856 proteins and quantify the expression of 3936. 347 were
signiﬁcantly diﬀerentially expressed between the two cell lines. For further validation, CD81, CBX-3, PHF6, and ENSA were
analyzed by western blot analysis. The results conﬁrmed the MS results. Immunohistochemical analysis on 59 formalin-ﬁxed
and paraﬃn-embedded (FFPE) normal and GCT tissue samples (normal testis, GCNIS, seminomas, and embryonal carcinomas)
of these proteins demonstrated the ability to distinguish diﬀerent GCT subtypes, especially seminomas and embryonal
carcinomas. In addition, siRNA-mediated knockdown of these proteins resulted in an antiproliferative eﬀect in TCam-2,
NTERA-2, and an additional embryonal carcinoma-like cell line, NCCIT. In summary, this study represents a proteomic
resource for the discrimination of malignant germ cell tumor subtypes and the observed antiproliferative eﬀect after knockdown
of selected proteins paves the way for the identiﬁcation of new potential drug targets.
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1. Introduction
Germ cell tumors (GCT) are the most common malignancies
in men between 15 and 40 years of age, and the incidence has
constantly increased over the last four decades [1]. Germ cell
tumors are histologically and clinically divided into semino-
mas and nonseminomas. Nonseminomas can be further
subdivided into embryonal carcinomas, yolk sac tumors,
chorionic carcinomas, and teratomas [2]. Seminomas and
nonseminomas have a common precursor called germ cell
neoplasia in situ (GCNIS) [3]. The International Germ
Cell Cancer Collaborative Group (IGCCCG) developed a
prognostic classiﬁcation system, which divided patients
with germ cell tumors into good-, intermediate, and
poor-risk groups. It is based besides on several points such
as the primary site of the GCT, metastatic sites of involve-
ment, and levels of serum tumor markers in particular
upon the histology of the tumors (seminoma versus non-
seminoma). Because the treatment of these tumors is dif-
ferent, it is important to diﬀerentiate between seminomas
and nonseminomas [4]. Patients even with metastasized
disease can be cured in about 80% of cases by cisplatin-
based chemotherapy [5, 6].
Several cell lines are available as models for the diﬀerent
types of GCT. NTERA-2 and NCCIT display embryonal
carcinoma characteristics; meanwhile, TCam-2 is considered
a model for seminoma [7, 8]. In this study, we set out to
establish new biomarkers for the diﬀerentiation of GCT cell
lines and formalin-ﬁxed and paraﬃn-embedded (FFPE) tis-
sue samples and to identify new potential drug targets to
improve the therapeutic options especially of patients with
embryonal carcinoma.
van der Zwan et al. performed a comprehensive study to
identify epigenetic footprints in TCam-2 and NCCIT cell
lines. They investigated interactions between gene expres-
sion, DNA CpG methylation, and posttranslational histone
modiﬁcations to elucidate their role in the pathophysiology
and etiology of germ cell tumors [9]. However, as the corre-
lation between genetic alterations, RNA expression, and pro-
tein expression is highly inﬂuenced by transcriptional,
translational, and posttranscriptional regulations [10], we
aimed for a global, unbiased, and quantitative analysis of
the two cell lines TCam-2 and NTERA-2 on the protein level.
With markers such as SALL4, OCT3/4, SOX-2, or SOX-
17, numerous good and reliable diagnostic markers are avail-
able to diﬀerentiate between the diﬀerent GCT subtypes [2,
11]. Regardless of this, it is of great importance to detect dif-
ferences in tumor biology in order to gain a better under-
standing of the pathological processes of germ cell tumors.
We reasoned that a proteomic approach, rather than geno-
mic and transcriptomic studies, can identify biological diﬀer-
ences and may also provide new potential targets for a
molecular targeted therapy. For this purpose, we employed
high-resolution mass spectrometric analysis combined with
stable isotope labelling with amino acids in cell culture
(SILAC) to visualize them in human testis and human germ
cell tumor tissue [12]. This strategy can help to minimize var-
iation occurring as a result of sample handling, because the
labelling occurs in a very early stage of the experiment [13].
2. Material and Methods
2.1. Culture of TGCT Cell Lines. In the present study, the
human GCT cell lines NTERA-2 (representing an embryonal
carcinoma, CRL 1973; from American Type Culture Collec-
tion, Manassas, VA, USA), NCCIT (representing an embryo-
nal carcinoma, CRL 2073; from American Type Culture
Collection, Manassas, VA, USA), and TCam-2 (representing
a seminoma; generously provided by the Department of
Developmental Pathology, University of Bonn Medical
School, Germany) were cultured in HEPES-buﬀered RPMI-
1640 (Biochrom, Berlin, Germany) supplemented with fetal
calf serum (FCS, 10%; CC Pro, Neustadt, Germany), penicil-
lin (100 IU/ml; Sigma-Aldrich, Munich, Germany), strepto-
mycin (100 μg/ml; Sigma-Aldrich), and L-glutamine
(2mM; Biochrom, Berlin, Germany). The incubation
temperature was 37°C in a humid atmosphere with 5%
carbon dioxide in the air.
2.2. Proteomic Analysis. Stable isotope labeling with amino
acids in cell culture (SILAC) and quantitative mass spec-
trometry were performed as described before [14–16].
TCam-2 and N-Tera2 cells were cultured in RPMI 1640
medium lacking arginine and lysine (Pierce) supplemented
with 10% dialyzed FCS (Invitrogen), 4mM glutamine, and
antibiotics. “Heavy” and “light” media were distinguished
by adding 0.115mM 13C6
14N4 L-arginine and 0.275mM L-
lysine-4,4,5,5-D4 (Eurisotop) or equimolar levels of the
corresponding nonlabeled (light) amino acids (Merck Milli-
pore), respectively. For cell lysis, 0.5% Nonidet P-40 buﬀer
containing 50mM Tris/HCl, pH7.8, 150mM NaCl, 1mM
Na3VO4, 1mM NaF, 0.2% lauryl maltoside, and protease
inhibitors (Complete, Roche) was used. Protein concentra-
tion was determined with DC Protein Assay (Bio-Rad) fol-
lowing the manufacturer’s instructions. Equal amounts of
protein of light-labeled TCam-2 were mixed with heavy-
labeled NTERA-2 and vice versa. Proteins were separated
by 1D-PAGE (4 to 12% NuPAGE Bis-Tris Gel, Invitrogen).
After Coomassie brilliant blue staining, the gel was divided
in 23 slices. Encompassing proteins were reduced with
10mM DTT for 55min at 56°C, alkylated with 55mM IAA
for 20min at 26°C, and gel-digested with modiﬁed trypsin
(Promega) overnight at 37°C.
Resulting peptides were separated by a C18 precolumn
(2.5 cm, 360 μm o.d., 100μm i.d., Reprosil-Pur 120Å, 5μm,
C18-AQ, Dr. Maisch GmbH) at a ﬂow rate of 10μl/min
and a C18 capillary column (20 cm, 360μm o.d., 75μm i.d.,
Reprosil-Pur 120Å, 3μm, C18-AQ, Dr. Maisch GmbH) at
a ﬂow rate of 300nl/min, with a gradient of acetonitrile rang-
ing from 5 to 35% in 0.1% formic acid for 90min using an
Proxeon nano LC coupled to an Q Exactive mass spectrome-
ter (Thermo Electron). MS conditions were as follows: spray
voltage, 1.8 kV; heated capillary temperature, 270°C; and
normalized collision-energy (NCE), 28. An underﬁll ratio
of 1.2% and intensity threshold of 4.0 e4 were used. The mass
spectrometer automatically switched between MS and
MS/MS acquisitions (data-dependent mode). Survey MS
spectra were acquired in the Orbitrap (m/z 350–1600) with
the resolution set to 70 000 at m/z 200 and automatic gain
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control target at 2 × e5. The 15 most intense ions were
sequentially isolated for HCD MS/MS fragmentation and
detection. Raw data were analyzed with MaxQuant (version
1.3.0.5) using Uniprot human (version 27.08.2012 with
86725 entries) as a sequence database. Up to two missed
cleavages of trypsin were allowed. Oxidized methionine was
searched as variable modiﬁcation and cysteine carbamido-
methylation as ﬁxed modiﬁcation. The modiﬁcations corre-
sponding to arginine and lysine labeled with heavy stable
isotopes were handled as ﬁxed modiﬁcations. The false posi-
tive rate was set to 1% at the peptide level, the false discovery
rate was set to 1% at the protein level, and the minimum
required peptide length was set to six amino acids.
2.3. Selection of Proteins for Further Investigations. To see
if the proteins detected in the SILAC assays are also
expressed in human testis tumor tissue, we compared
the signiﬁcantly expressed proteins of our results with
the data in the online database The Human Protein Atlas
(https://www.proteinatlas.org/) [17]. In the selection, we
exemplarily opted for proteins that were expressed in
tumor-free testicular tissue, with the consideration that
these proteins could possibly be of particular importance
in testicular tumors.
2.4. Western Blot Analysis. Total protein lysates were
prepared using RIPA buﬀer with protease inhibitors (Roche,
Germany) and were quantiﬁed by the Bio-Rad DC Protein
Assay (Bio-Rad, USA). For western blotting, the following
primary antibody dilutions were used: monoclonal mouse
anti-CD81 (Tetraspanin-28) (Santa Cruz, sc-166029;
1 : 250), monoclonal mouse anti-PHF6 (PHD ﬁnger pro-
tein 6) (Santa-Cruz, sc-365237; 1 : 500), polyclonal rabbit
anti-CBX-3 (chromobox protein homolog 3) (HPA 004902,
Sigma-Aldrich; 1/250), and polyclonal rabbit anti-ENSA
(alpha-endosulﬁne) (HPA 051292, Sigma-Aldrich: 1/500).
Primary antibodies were detected by polyclonal immunoglo-
bulins/HRP secondary antibodies (1 : 1000, Dako, DK).Mem-
branes were developed using the ECL system (Amersham
Bioscience, Germany).
2.5. Gene Ontology and Network Analysis. Gene ontology
classiﬁcation has been performed using either the Metacore
software (https://portal.genego.com/) or the R package
clusterProﬁler. Diﬀerentially expressed proteins were loaded
into Metacore software, and signiﬁcantly enriched biologi-
cal processes, molecular functions, and pathway networks
were extracted.
Network analyses were performed using the Metacore
(https://portal.genego.com/) software for the enrichment of
the shortest pathways inside the group of diﬀerentially
regulated proteins. The shortest path algorithm connects
the diﬀerentially expressed proteins identiﬁed in the proteo-
mic approach with additional information from the Meta-
core database along a directed path and potentially involved
pathways. Next, most signiﬁcant networks were loaded into
Cytoscape software (http://www.cytoscape.org/) for further
visualization. Networks were visualized using hierarchical
layout in Cytoscape.
2.6. Tissue Samples of Primary TGCT. Formalin-ﬁxed and
paraﬃn-embedded tumor tissues of orchiectomy specimens
were collected from 59 male patients from the University
Medical Centre Göttingen, Germany. Tumors were classi-
ﬁed and staged on the basis of the WHO classiﬁcation
[18]. In the present study, a number of 75 blocks have been
included. Investigated cases included normal testis adjacent
to tumor (n = 16), GCNIS (n = 18), seminomas (n = 21),
and embryonal carcinomas (n = 20). Ethical approval for
using the human material in the present study was
obtained from the Ethics Committee of the University
Medical Centre Göttingen.
2.7. Immunohistochemistry. Immunohistochemical reactions
were performed on 4μm formalin-ﬁxed and paraﬃn-
embedded testis tissue sections. In heat-induced epitope
retrieval, the antigen retrieval was carried out at 98°C in
citrate buﬀer (low pH6; 40 minutes) or EDTA buﬀer (high
pH9; 20 minutes). The primary antibodies were incubated
for 30 minutes at room temperature. The following antibod-
ies and dilutions were applied: anti-CD81 (mouse, high
buﬀer, 1 : 200, Santa Cruz, sc-166029), anti-PHF6 (mouse,
high buﬀer, 1 : 200, Santa-Cruz, sc-365237), anti-CBX-3 (rab-
bit, diluted 1/200, high buﬀer, HPA 004902, Sigma-Aldrich),
and anti-ENSA (rabbit, diluted 1/50, low buﬀer, HPA
051292, Sigma-Aldrich). Afterwards, the sections were incu-
bated with a ready-to-use HRP-labeled secondary antibody
at room temperature for 25 minutes (anti-rabbit/mouse, pro-
duced in goat; Dako REAL EnVision Detection System,
DAKO). The substrate DAB+ Chromogen system produces
a brown end product and is applied to visualize the site of
the target antigen (Dako REAL DAB+ Chromogen, DAKO).
Tissue samples were counterstained with Meyer’s hematoxy-
lin (Dako) for 8 minutes and were analyzed by light
microscopy.
Two independent investigators evaluated all tissue sec-
tions stained for CD81, CBX-3, PHF-6, and ENSA using
an immunoreactivity staining score (IRS) as described pre-
viously [18, 19]. The percentage of positively stained cells
was ﬁrst classiﬁed using a 0–4 scoring system: score
0= 0% positive cells, score 1 = less than 10% positive cells,
score 2=10–50% positive cells, score 3= 51–80% positive
cells, and score 4=>80% positive cells. The intensity of
staining was evaluated on a four-tiered scale (0 =negative,
1 =weak, 2 = intermediate, and 3= strong). Afterwards, the
scores of intensity and staining were multiplied, and the
mean value per patient was calculated, as described previ-
ously [18]. Diﬀerences of IRS between the diﬀerent subtypes
of GCT were statistically evaluated using Student’s t-test
(GraphPad Software, San Diego, CA, USA). A p value of
<0.05 was considered signiﬁcant.
2.8. siRNA Transfection. Tumor cells were transfected with
100 μl transfection mix (12μl HiPerFect, Qiagen, Hilden,
Germany, 2.5μl siRNA (20μM), and 85.5μl RPMI medium).
siRNAs used were Hs_PHF6_10, SI05120745 and Hs_PHF6_
11, SI05120752; Hs_CD81_6, SI02777236 and Hs_CD81_7,
SI02777243; Hs_CBX-3_6, SI02665222 and Hs_CBX-3_7,
SI03028165; and Hs_ENSA_20, SI05062218 and Hs_
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ENSA_21, SI05062225 (Qiagen, Hilden, Germany). After
incubation for 20min, 100 μl siRNA medium were mixed
with 2.3ml culture medium to create a concentration of
1 : 1000. The cells were incubated for 24 h or 48h.
2.9. Measurement of Cell Proliferation. 1 × 105 to 3 × 105 cells
were plated as described above. After 48h incubation time,
the culture medium was exchanged for a siRNA medium
(2.3ml culture medium, 100μl siRNA-Mix). For cell viability
analysis, equal numbers of cells were seeded into 96-well
ﬂat-bottom plates and incubated for indicated time points.
Cell viability was determined by the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (MTS) (Promega)
according to the manufacturer’s instructions.
3. Results
3.1. Quantitative Proteomic Proﬁling of TCam-2 and
NTERA-2. In order to ﬁnd diﬀerences in the global proteome
of seminoma-like and embryonal carcinoma-like cell lines,
we performed a quantitative protein expression analysis by
SILAC-based mass spectrometry. The cell lines TCam-2
(representing cell line with seminoma characteristics) and
NTERA-2 (representing a cell line with embryonal carci-
noma characteristics) were cultured with light and heavy
isotope-labeled amino acids as described in the Material
and Methods. After cell lysis, equal amounts of protein of
light-labeled TCam-2 were mixed with heavy-labeled
NTERA-2 and vice versa and subsequently analyzed by
high-resolution mass spectrometry. Due to the incorporation
of SILAC amino acids, proteins derived from both cell lines
can be accurately assigned to the two cell lines and its expres-
sion and can be comparatively quantiﬁed (Figure 1(a)). In
two biological replicates, a total of 4856 proteins were identi-
ﬁed and 3936 proteins could be quantiﬁed with a Gaussian
distribution of the ratios between the two cell lines
(Figure 1(b)). Next, an outlier signiﬁcance score depending
on intensity values (signiﬁcance B in Perseus, see citation
for more details [20, 21]) was calculated for every protein.
347 proteins showed a signiﬁcantly diﬀerent expression and
196 (TCam-2) and 102 (NTERA-2) proteins showed an at
least 2.5-fold increased expression. The complete list of iden-
tiﬁed proteins detected by the quantitative MS is given in
supplementary table 1, and the complete list of diﬀerentially
expressed proteins is given in supplementary table 2.
3.2. Bioinformatics Analysis Reveals Diﬀerential Pathway
Activation Patterns. The proteins showing signiﬁcantly dif-
ferential expression based on the results of the quantitative
proteomic approach were subjected to a GO term analysis
by the Metacore software (https://portal.genego.com/). The
regulated proteins were found to be involved in diﬀerent bio-
logical processes such as the regulation of tissue development
or ion transport.
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Figure 1: Proteomic proﬁling of testicular germ cell cancer cell lines. Workﬂow of SILAC-based mass spectrometry experiments. TCam-2
and NTERA-2 were metabolically labeled with amino acids of diﬀerent masses allowing a comprehensive relative quantiﬁcation of protein
expression by mass spectrometry (a). Distribution of SILAC ratios of all quantiﬁed proteins according to their relative expression in
NTERA-2 and TCam-2 (b).
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Network analysis was also performed using the Meta-
core (https://portal.genego.com/) software for the enrich-
ment of the shortest pathways inside the groups of
diﬀerentially regulated proteins, as described above. Supple-
mentary table 3 gives an overview of the networks found to
be the most signiﬁcantly involved. Inside the networks,
diﬀerentially regulated proteins identiﬁed by the MS
approach are indicated in green for TCam-2 (representing
seminomatous histology) or in red for NTERA-2
(representing nonseminomatous histology). Blue proteins
represent proteins that were added from the Metacore
database as potentially linked to the proteins derived from
the MS analysis which are involved in diﬀerent processes
such as proteins which play a crucial role, for example,
in gastrulation, endoderm development, or formation of
a primary germ layer (Figure 2(a)) or mammary gland
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Figure 2: Results of network analysis: diﬀerentially regulated proteins from the SILAC approach are indicated in green (TCam-2) or in red
(NTERA-2). Blue proteins represent proteins that were added from the Metacore database as potentially linked to the proteins from the
SILAC analysis which are involved e.g. in gastrulation, endoderm development or formation of primary germ layer (a) and which are
involved, e.g., in mammary gland development or ﬁbroblast growth factor receptor signaling pathway (b). TR: transcription regulation;
+P: phosphorylation; B: binding.
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development or ﬁbroblast growth factor receptor signaling
pathway (Figure 2(b)).
3.3. In Vitro and In Vivo Validation of Diﬀerentially
Expressed Proteins. To validate the results of the proteomics
approach, four proteins were selected showing signiﬁcant
diﬀerences in expression between the two GCT-cell lines
and which showed a physiological expression in nonneoplas-
tic germ cells or several stages of spermatogenesis (according
to The Human Protein Atlas database [17]), namely, CD81,
CBX-3, PHF-6, and ENSA. In order to verify the diﬀerential
protein expression, we additionally examined a third cell line
named NCCIT (showing EC characteristics also).
Western blot analyses conﬁrmed the results of the quan-
titative proteomic proﬁling. According to MS, the amount of
CD81 (ratio TCam − 2/NTERA − 2 = 3 625) and CBX-3
(ratio TCam − 2/NTERA − 2 = 3 281) protein was signiﬁ-
cantly higher in TCam-2 than in NTERA-2- cells (supple-
mentary table 2). These diﬀerences could be reproduced by
western blot analysis for CD81 and CBX-3 which showed a
marked diﬀerence in expression between the two cell lines
with embryonal carcinoma characteristics (NTERA-2- and
NCCIT) and TCam-2 (seminoma characteristics)
(Figures 3(a) and 3(b)). In contrast, expression of PHF6
(ratio NTERA − 2/TCam − 2 = 3 841) and ENSA (ratio
NTERA − 2/TCam − 2 = 2 707) proteins was signiﬁcantly
higher in NTERA-2 than in TCam-2 cells (supplementary
table 2). These diﬀerences could also be reproduced by
western blot analysis for PHF6 and ENSA, which showed
marked diﬀerences in protein expression in NTERA-2 and
NCCIT compared to TCam-2 (Figures 3(c)and 3(d)). The
results conﬁrmed the same expression pattern of NCCIT-
and NTERA-2 cells in contrast to TCam-2 cells.
To conﬁrm the results of the western blot analyses and
gain insight into expression patterns within single cells of
primary tumors (i.e., nuclear, cytoplasmic, or membranous
staining), commercially available antibodies against CD81,
CBX-3, PHF-6, and ENSA were used for immunohistochem-
ical analysis of human tissues. FFPE tissue samples of 59
patients with malignant GCT of the testis were investigated
by immunohistochemical analysis. The investigated samples
comprised tumor-free testicular tissue (n = 16), GCNIS
(n = 18), seminomas (n = 21), and embryonal carcinomas
(n = 20). Seminomas (to compare with TCam-2 cells) and
embryonal carcinomas (to be compared with NTERA-2
and NCCIT cells) were explicitly chosen for direct a compar-
ison with the cell lines.
A tumor-free testis showed a strong membranous and
cytoplasmic expression of CD81 protein (Figure 4(a), arrow).
In germ cell neoplasia in situ (GCNIS), a similar pattern
of membranous and cytoplasmic expression was found
(Figure 4(b), arrow). All investigated seminomas showed
a strong membranous expression of CD81 in tumor cells
(Figure 4(c), arrow). In contrast, no or only a weak staining
of CD81 was seen in embryonal carcinoma cells (Figure 4(d),
arrow). The diﬀerences in staining intensity (according to the
immunoreactivity staining score (IRS)) of CD81 (Figure 4(e))
observed between seminomas and embryonal carcinomas
were marked and showed a statistical signiﬁcance.
CBX-3 protein showed a strong nuclear expression in
spermatogonia, in contrast to a weaker expression in sper-
matocytes and spermatids (Figure 4(f), arrow). In addition,
a strong nuclear expression of CBX-3 was observed in
GCNIS (Figure 4(g), arrow). A strong nuclear expression
was also detected in most seminoma cells (Figure 4(h),
arrow). A much weaker nuclear expression of CBX-3 was
seen in embryonal carcinomas (Figure 4(h), arrow). The dif-
ferences in staining intensity (according to the immunoreac-
tivity staining score (IRS)) of CBX-3 (Figure 4(j)) observed
between seminomas and embryonal carcinomas were
marked and showed a statistical signiﬁcance. The results of
CD81 and CBX-3 immunohistochemistry conﬁrmed the
ﬁndings of the proteomic and western blot analyses.
Immunohistochemically, PHF-6 protein showed strong
nuclear expression in spermatogonia and slightly weaker
expression in sertoli cells, whereas later stages of sper-
matogenesis did not express PHF-6 (Figure 5(a), arrow).
The expression of PHF-6 in GCNIS was heterogeneous,
with some nuclei showing strong and others weak or no
expression (Figure 5(b), arrow). Seminomas showed no or
-26-
-42-
NTERA-2 TCam2kDa
CD 81
𝛽-Actin
NCCIT
(a)
kDa
-21-
-42-
CBX-3
𝛽-Actin
NTERA-2 TCam2NCCIT
(b)
kDa
-41-
-42-
PHF-6
𝛽-Actin
NTERA-2 TCam2NCCIT
(c)
kDa
ENSA-15-
-42- 𝛽-Actin
NTERA-2 TCam2NCCIT
(d)
Figure 3: In vitro validation of diﬀerentially expressed proteins. In line with the results of the SILAC method and mass spectrometry, CD81
and CBX-3 show markedly higher expression in TCam-2 than in NTERA-2 (a, b). Conversely, PHF-6 and ENSA show markedly higher
expression in NTERA-2 than in TCam-2 cells (c, d).
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Figure 4: Immunohistochemical analysis of selected proteins (more highly expressed in TCam-2 than in NTERA-2) in tumor-free testis,
GCNIS, seminoma, and embryonal carcinoma: a tumor-free testis and GCNIS show no diﬀerences in CD81 and CBX-3 >expression (a, b,
f, g). The expression of CD81 and CBX-3 in embryonal carcinomas (d, i) is signiﬁcantly lower than that in seminomas (c, h). The
diﬀerences between seminomas and embryonal carcinomas in staining intensity (IRS) of CD81 (i) and CBX-3 (j) are signiﬁcant.
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Figure 5: Immunohistochemical expression of selected proteins (more highly expressed in NTERA-2 than in TCam-2) in a tumor-free testis,
GCNIS, seminoma, and embryonal carcinoma: A tumor-free testis and GCNIS show no marked diﬀerences in protein expression of PHF-6
and ENSA on immunohistochemical analysis (a, b, f, g). The expression of PHF-6 and ENSA in embryonal carcinomas (d, i) is markedly
higher than that in seminomas (c, h; white arrow tumor cells, black arrow lymphocytes). The diﬀerences between seminomas and
embryonal carcinomas in staining intensity (IRS) of PHF-6 € and ENSA (j) are signiﬁcant.
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only minimal expression of PHF-6 protein. Beside the tumor
cells, lymphocytes also expressed PHF-6 (Figure 5(c),
arrows). In contrast, embryonal carcinoma cells showed a
strong nuclear expression of PHF-6 (Figure 5(d), arrow).
The diﬀerences in staining intensity (according to the immu-
noreactivity staining score (IRS)) of PHF-6 (Figure 5(e))
observed between embryonal carcinomas and seminomas
were marked and showed a statistical signiﬁcance.
ENSA showed a strong nuclear and weak cytoplasmic
expression in late stages of spermatogenesis, whereas sper-
matogonia were only weakly positive for ENSA (Figure 5(f),
arrow). In addition, ENSA was found to be strongly
expressed in GCNIS, mostly nuclear (Figure 5(g), arrow).
Seminoma cells showed only a moderate nuclear expression
of ENSA (Figure 5(h), arrow). Interestingly, nuclear as well
as cytoplasmic expression of ENSA in embryonal carcino-
mas was signiﬁcantly stronger than that in seminomas
(Figure 5(i), arrow).
The diﬀerences in staining intensity (according to the
immunoreactivity staining score (IRS)) of ENSA (Figure 5(j))
observed between embryonal carcinomas and seminomas
were marked and showed a statistical signiﬁcance. The
results of PHF-6- and ENSA-immunohistochemistry con-
ﬁrmed the proteomic and western blot ﬁndings.
3.4. Knockdown of Selected Proteins Results in Reduction of
Cellular Survival in Seminoma and EC Cell Lines. To gain
insight into involved cellular processes and the putative role
of selected proteins detected by MS, siRNA experiments were
performed. The tumor cell lines NCCIT, NTERA-2, and
TCam-2 were transfected with two speciﬁc siRNAs to
achieve knockdown of CD81, CBX-3, PHF-6, and ENSA
as described above. A marked downregulation of protein
expression was achieved for all proteins for both siRNAs
used (Figures 6(a)–6(d)).
This downregulation had no eﬀect on proliferation after
24 h (data not shown). 48 h after downregulation of CD81,
we observed a signiﬁcant decrease of proliferation in NTERA-
2, NCCIT, and TCam-2 cells. In NCCIT and NTERA-2, trans-
fection with siRNA2 showed no statistical signiﬁcances in
proliferation (Figures 7(a)–7(c)). After the downregulation
of CBX-3, we also observed a signiﬁcant decrease of prolifer-
ation in all investigated GCT cell lines. SiRNA2 showed no
statistical signiﬁcances in proliferation in NTERA-2 cells
(Figures 7(a)–7(c)). After the downregulation of PHF-6, we
observed a signiﬁcant decrease of proliferation in all investi-
gated GCT cell lines, too. SiRNA2 had no eﬀect in prolifera-
tion in TCam-2 cells (Figures 7(a)–7(c)). Finally, we
observed a signiﬁcant decrease of proliferation in all investi-
gated GCT cell lines after downregulation of ENSA. SiRNA2
showed no statistical signiﬁcances in proliferation in NCCIT
cells (Figures 7(a)–7(c)). The decrease in proliferation after
siRNA transfection appears to be independent of the diﬀerent
levels of expression of the proteins, as one might suspect.
4. Discussion
GCTs are highly interesting tumors, both from a point of
view of developmental biology and considering their tumor
biology. GCTs are divided into seminomas and nonsemino-
mas [2]. For in vitro studies, several GCT cell lines are well
established, such as TCam-2 (with seminoma characteris-
tics), NTERA-2, and NCCIT (both with characteristics of
embryonal carcinomas) [7, 8, 22, 23]. We aimed to identify
new biomarkers for the diﬀerentiation of GCT cell lines on
the protein level. A recent study by van der Zwan et al. iden-
tiﬁed epigenetic footprints in TCam-2 and NCCIT cell lines.
These analyses conﬁrmed a more germ cell-like proﬁle in
TCam-2 cells and, in contrast, a more pluripotent phenotype
in NCCIT cells [9]. We compared the results of a diﬀerential
gene expression in TCam-2 and NCCIT cells of the work by
van der Zwan et al. [9] to the results of our project and found
44 (TCam-2) and 23 (NTERA-2 or NCCIT) similarly signif-
icantly diﬀerentially expressed proteins/genes. The exact
names of the genes are listed in Table 1. This underpins the
potential importance of these genes in the biology of these
tumor cells.
In addition, we searched for proteins that were diﬀerently
expressed in cell lines and that are expressed physiologically
in spermatogonia and later stages of spermatogenesis. Fur-
thermore, we analyzed if the ﬁndings from the cell line
experiments were reproducible in FFPE tissue samples of
human GCTs. In the present study, 111 proteins showed
a statistically signiﬁcant two-fold increase in expression
in TCam-2 compared to NTERA-2. Inﬂuenced by the
expression pattern in spermatogenesis and germ cell
tumors (according to The Human Protein Atlas database
[17]) by the availability of antibodies and their applicability
on both, cell lines and FFPE tissues, we chose the proteins
CD81 (ratio from SILAC-analysis TCam-2/NTERA-2:
3.626) and CBX-3 (ratio TCam-2/NTERA-2: 3.282) for
further investigations.
CD81 is a cell surface protein of the tetraspanin family. It
is widely expressed on many healthy tissues and on the
majority of tumor cells. Vences-Catalan et al. demonstrated
in comprehensive studies the role of CD81 as a promoter of
tumor growth and metastasis with a putatively important
role in tumor progression [24, 25]. Zhang et al. described that
an increased expression of CD81 was signiﬁcantly associated
with reduced overall survival in patients with mammary car-
cinoma. Furthermore, CD81 knockdown results in decreased
proliferation andmigration in mammary carcinoma cell lines
in vitro [26]. In addition, Hong et al. described that CD81
increases melanoma cell motility by upregulating the metal-
loproteinase MT1-MMP-expression. This could be explained
by a prooncogenic Akt-dependent Sp1 activation [27]. Inter-
estingly, in our study, we could demonstrate that CD81
showed marked diﬀerences in its expression when compar-
ing seminoma (high expression) and embryonal carcinoma
tissue samples (low expression). CD81 interacts with CD9
(another member of the tetraspanin family), which is also
signiﬁcantly upregulated in TCam-2 cells (supplementary
table 2), and both play an important role in the TGF beta
signaling pathway in melanoma cells [28]. TGF beta, EGF,
and FGF have been shown to play a role in the
diﬀerentiation of TCam-2 into a cell type resembling a
mixed nonseminoma [7]. This would be in line with the
ﬁndings of our study, as shown in Figure 2, where involved
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networks are displayed and demonstrate that these growth
factor signaling pathways play a crucial role. In addition,
ﬁrst investigations with two siRNAs against CD81 showed a
signiﬁcant reduction of proliferation in TCam-2 cells, as
well as in NTERA-2 and NCCIT cells (Figure 7). So the
extent of proliferation seems not to correlate with the
expression level of CD81. Usually, TCam-2 cells proliferate
remarkably slower than NTERA-2 and NCCIT. However,
the high expression of CD81 on TCam-2 and seminoma
samples is interesting given the induction of nonseminoma-
like phenotype by TGF beta signaling [6]. However, the
exact mechanism on how the proliferation was reduced in
this cell line has not been investigated in more detail and
remains to be elucidated.
A second protein which was markedly higher expressed
in TCam-2 cells than in NTERA-2 and NCCIT cells is
CBX-3. Little is known about the function of CBX-3 in cancer
cells. One study could demonstrate the essential function of
CBX-3 for male germ cell survival and spermatogenesis
[29]. Ma et al. described very recently that the expression of
CBX-3 in osteosarcomas is associated with a large tumor size,
high distant metastasis rate, and high clinical stage rate.
Furthermore, they could show that knockdown of CBX-3
by siRNA results in increased apoptosis and cell cycle
arrest at the G0 and G1 phases [30]. Another recent study
demonstrates the role of CBX-3 in tumor progression in
pancreatic cancer cell lines. It could be shown that the
tumor-promoting eﬀect of CBX-3 might be mediated by
CDK1 [31]. Further similar results were demonstrated by
Zhang et al. which demonstrate that a high expression of
CBX-3 in squamous carcinomas of the tongue is associ-
ated with poor prognosis. In addition, the inhibition of
CBX-3 leads to cell cycle delay via the p21 pathway [32].
Similar ﬁndings were described by Fan et al. who showed
that CBX-3 promotes the progression of the cell cycle and
proliferation in vitro and in vivo in colon cancer cells.
They could explain that CBX-3 promotes colon cancer cell
proliferation by curbing cell cycle G1-S phase transition
[33]. Another study showed a high expression of CBX-3
in various human cancer tissues and suppression of tumor
growth of various cancer-derived cell lines following
siRNA-mediated knockdown [34]. Again, we found that
two siCBX-3 reduced tumor cell growth in all investigated
GCT cell lines. Further investigations of the mechanisms
underlying this observation and a potential role in antitu-
mor therapy are pending.
Our investigations furthermore showed markedly
higher expression of PHF-6 in NTERA-2 and NCCIT cell
lines as compared to TCam-2. PHF-6 is a gene found in
association with the Börjeson-Forssman-Lehmann syndrome
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Figure 6: Transfection with siRNA markedly reduces protein expression of CD81, CBX-3, PHF-6, and ENSA: NCCIT, NTERA-2, and
TCam-2 were transfected with a siRNAs against CD81, CBX-3, PHF-6, and ENSA. The protein expression was markedly reduced after
transfection with siRNA (a–d).
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[35]. Interestingly, patients with this syndrome generally
show hypogonadism [36]. Our results show a strong nuclear
positivity of the PHF-6 protein in normal spermatogenesis
and GCNIS, whereas the expression in seminomas was mark-
edly lower. Notably, PHF-6 expression was markedly higher
in embryonal carcinomas, than in seminomas in FFPE
samples. Recently, PHF-6 has been described to be involved
in regulating rRNA synthesis, which may contribute to its
role in cell cycle control, maintenance of genomic integrity,
and tumor suppression [37]. This would be in line with our
results which show that siPHF-6 suppresses cell proliferation
in GCT cell lines (Figure 7).
Finally, ENSA (alpha-endosulﬁne) is a potent inhibitor of
PP2A-B55δ [38, 39]. PP2A is expressed in both primary
GCTs and GCT cell lines. Its inhibition mediates an apopto-
sis induction in GCT cells through activation of the MEK-
ERK signaling pathway [40]. Furthermore, inhibition of
ENSA with two speciﬁc siRNAs leads to reduced cell prolifer-
ation in all investigated GCT cell lines. Seminoma cells
showed only a moderate nuclear expression (Figure 5(h)),
in contrast to embryonal carcinomas which show a signif-
icantly stronger expression of ENSA than seminomas.
However, this ﬁnding supports the close developmental
relationship between early spermatogenesis and semino-
mas in contrast to embryonal carcinomas.
Using network analysis, the diﬀerently expressed proteins
identiﬁed by our proteomic analysis could be linked to the
proteins assigned from the Metacore database. Proteins were
closely linked to proteins such as SOX-2, SOX-17, NANOG,
or OCT3/4, which all have been described to play crucial
roles in pluripotency and diﬀerentiation of germ cells and
germ cell tumors [41–43]. Interestingly, another putative
stem cell gene, GDF-3, has been found to be expressed in
both seminomas and breast carcinomas [42]. The increased
expression of BCAT1 in NTERA-2 cells compared to
TCam-2 cells seems also of interest in distinguishing germ
NCCIT
0.0
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
0.5
1.0
1.5
⁎⁎⁎
n.s.
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎
⁎⁎⁎
n.s.
Ce
ll 
nu
m
be
r
ctrl
cd81
CBX3
PHF6
ENSA
(a)
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
NTERA-2
0.0
0.5
1.0
1.5
Ce
ll 
nu
m
be
r
⁎⁎⁎
⁎⁎ ⁎⁎
⁎⁎⁎
n.s. n.s.
⁎ ⁎
ctrl
cd81
CBX3
PHF6
ENSA
(b)
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
siR
N
A
2
siR
N
A
1
TCam-2
0.0
0.5
1.0
1.5
Ce
ll 
nu
m
be
r
⁎⁎⁎
⁎⁎
n.s.
⁎
⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎
ctrl
cd81
CBX3
PHF6
ENSA
(c)
Figure 7: Transfection with siRNA decreases cell proliferation of GCT cell lines: in all investigated tumor cell lines, NCCIT (a), NTERA-2 (b),
and TCam-2 (c), proliferation was signiﬁcantly reduced after transfection with siRNA against CD81, CBX-3, PHF-6, and ENSA.
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cell tumor subtypes. These ﬁndings are in line with the
results of Rodriguez et al., which could demonstrate a
strong overexpression of BCAT-1 in nonseminomas germ
cell tumors [44].
5. Conclusion
In summary, high-resolution mass spectrometry in combina-
tion with SILAC-quantiﬁcation is suitable for the detection of
diﬀerentially expressed proteins in GCT cell lines. These
results could be reproduced by western blot analysis. Proteins
detected as diﬀerentially expressed by SILAC-basedMS could
furthermore be validated in FFPE samples of human GCTs
and normal (tumor-free) testes. This method is therefore
valuable for the detection of new markers with the potential
to distinguish between diﬀerent histologic subtypes of these
tumors. In addition, network analyses serve to classify the dif-
ferentially expressed proteins into functional groups. Finally,
siRNA results indicate an antiproliferative potential of the
therapeutic knockdown of several detected proteins, which
warrants their evaluation as potential therapeutic targets.
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Supplementary 1. Supplementary Table 1 Complete list of
identiﬁed proteins detected by the quantitative mass spec-
trometry as revealed by MaxQuant analysis of the obtained
MS raw data.
Supplementary 2. Supplementary Table 2 Diﬀerentially
expressed proteins in TCam-2 and NTERA-2.
Table 1: Diﬀerentially expressed genes compared with van der
Zwan et al. [9] and the results of the present study. The table
shows the identical genes, which are diﬀerentially expressed in
NCCIT or NTERA-2 compared to TCam-2.
Increased in TCam-2 Increased in NTERA-2/NCCIT
ACSF2 ACAT2
ANXA1 AP1S2
ANXA3 ARMCX2
CACNA2D2 ARRB1
COL17A1 ASS1
COL23A1 BCAT1
COMT C1QBP
CSRP1 CECR5
DUSP23 CRABP1
EFR3A CTSC
ENO2 DPYSL3
EPCAM GFPT2
FLNC HPRT1
GLIPR2 IQGAP2
GMPR MAD2L2
GSN MGST1
HEG1 PFAS
HIC2 PNMA2
ITGAV POLR3G
LAMA5 SH3BGRL
ODZ4 SOX2
PHLDA3 TMCO1
PPM1F UGP2
PRAME
PROM1
PSD3
PSTPIP2
PVR
PYGB
RAB15
RASSF2
RCN1
SDF2L1
SERPINE2
SLC25A29
SPARC
TAGLN
TCL1A
TFAP2C
TMEM132A
VAMP8
VSNL1
WASL
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Supplementary 3. Supplementary Table 3. Signiﬁcantly
involved networks of proteins detected by SILAC and mass
spectrometry.
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